

PROXYMED INC /FT LAUDERDALE/
Form SC 13D/A
December 10, 2003

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1)

PROXYMED, INC.
(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE
(Title of Class of Securities)

744290305
(CUSIP Number)

THOMAS J. MURPHY
C/O GENERAL ATLANTIC SERVICE CORPORATION
3 PICKWICK PLAZA
GREENWICH, CONNECTICUT 06830
TEL. NO.: (203) 629-8600
(Name, Address and Telephone Number of
Person Authorized to Receive Notices
and Communications)

DECEMBER 5, 2003
(Date of Event which Requires Filing
of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 1(f) or 1(g), check the following box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

744290305

Page 2 of 22

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

General Atlantic Partners, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	7	SOLE VOTING POWER
		-0-
NUMBER OF	8	SHARED VOTING POWER
SHARES		2,118,645
BENEFICIALLY OWNED BY EACH		
REPORTING	9	SOLE DISPOSITIVE POWER
PERSON		-0-
WITH	10	SHARED DISPOSITIVE POWER
		2,118,645

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,118,645

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

28.9%

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

14 TYPE OF REPORTING PERSON

OO

744290305

Page 3 of 22

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

General Atlantic Partners 74, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	7	SOLE VOTING POWER
		-0-
NUMBER OF SHARES	8	SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		2,118,645
	9	SOLE DISPOSITIVE POWER
		-0-
	10	SHARED DISPOSITIVE POWER
		2,118,645

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,118,645

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

28.9%

14 TYPE OF REPORTING PERSON

PN

744290305

Page 4 of 22

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

GAP Coinvestment Partners II, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	7	SOLE VOTING POWER
		-0-
NUMBER OF	8	SHARED VOTING POWER
SHARES		2,118,645
BENEFICIALLY OWNED BY EACH		
REPORTING	9	SOLE DISPOSITIVE POWER
PERSON		-0-
WITH	10	SHARED DISPOSITIVE POWER
		2,118,645

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,118,645

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

28.9%

14 TYPE OF REPORTING PERSON

PN

744290305

Page 5 of 22

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

GapStar, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)

[]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	7	SOLE VOTING POWER
		-0-
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER
		2,118,645
	9	SOLE DISPOSITIVE POWER
		-0-
	10	SHARED DISPOSITIVE POWER
		2,118,645

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,118,645

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

28.9%

14 TYPE OF REPORTING PERSON

OO

744290305

Page 6 of 22

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

GAPCO GmbH & Co. KG

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Germany

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER
	-0-	
	8	SHARED VOTING POWER
	2,118,645	
	9	SOLE DISPOSITIVE POWER
	-0-	
	10	SHARED DISPOSITIVE POWER
	2,118,645	

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,118,645

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

28.9%

14 TYPE OF REPORTING PERSON

PN

744290305

Page 7 of 22

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

GAPCO Management GmbH

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Germany

	7	SOLE VOTING POWER
		-0-
NUMBER OF SHARES	8	SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH REPORTING PERSON		2,118,645
WITH	9	SOLE DISPOSITIVE POWER
		-0-
	10	SHARED DISPOSITIVE POWER

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

2,118,645

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,118,645

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

28.9%

14 TYPE OF REPORTING PERSON

CO

744290305

Page 8 of 22

ITEM 1. SECURITY AND ISSUER.

This Amendment No. 1 ("Amendment No. 1") to Schedule 13D is filed by the undersigned to amend and supplement the Schedule 13D, dated April 5, 2002 (the "Original Schedule 13D"), with respect to the shares of Common Stock, par value \$0.001 per share (the "Common Stock"), of ProxyMed, Inc., a Florida corporation (the "Company"). The address of the principal executive office of the Company is 2555 Davie Road, Suite 110, Fort Lauderdale, Florida 33317.

ITEM 2. IDENTITY AND BACKGROUND.

ITEM 2 IS HEREBY AMENDED AND RESTATED IN ITS ENTIRETY AS FOLLOWS:

This statement is being filed by a group, as defined in Rule 13d-5 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The members of the group are General Atlantic Partners, LLC, a Delaware limited liability company ("GAP"), General Atlantic Partners 74, L.P., a Delaware limited partnership ("GAP 74"), GAP Coinvestment Partners II, L.P., a Delaware limited partnership ("GAPCO II"), GapStar, LLC, a Delaware limited liability company ("GapStar"), GAPCO GmbH & Co. KG, a German limited partnership ("KG"), and GAPCO Management GmbH, a German corporation ("GmbH Management" and, collectively with GAP, GAP 74, GAPCO II, GapStar and KG, the "Reporting Persons"). The Reporting Persons (other than KG and GmbH Management) are located at 3 Pickwick Plaza, Greenwich, Connecticut 06830. KG and GmbH Management are located c/o General Atlantic Partners GmbH, Koenigsallee 62, 40212 Duesseldorf, Germany. Each of the Reporting Persons is engaged in acquiring, holding and disposing of interests in various companies for investment purposes. The general partner of GAP 74 is GAP. GAP is also the Managing Member of GapStar. GmbH Management is the

744290305

Page 9 of 22

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

general partner of KG. The managing members of GAP are Steven A. Denning, Peter L. Bloom, Peter L.S. Currie, Mark F. Dzialga, Erik Engstrom, Klaus Esser, David C. Hodgson, William O. Grabe, William E. Ford, Braden R. Kelly, Rene M. Kern, Marc F. McMorris, Matthew Nimetz, Clifton S. Robbins, Franchon M. Smithson, Tom C. Tinsley, Philip P. Trahanas, Florian Wendelstadt and John Wong (collectively, the "GAP Managing Members"). The GAP Managing Members (other than Mr. Esser) are also the general partners of GAPCO II. The business address of each of the GAP Managing Members (other than Messrs. Esser, Currie, Kelly, Tinsley, Wendelstadt and Wong) is 3 Pickwick Plaza, Greenwich, Connecticut 06830. The business address of Mr. Esser is Koenigsallee 62, 40212, Duesseldorf, Germany. The business address of Mr. Wendelstadt is 83 Pall Mall, Sixth Floor, London SW1Y 5ES, United Kingdom. The business address of Messrs. Currie and Kelly is 228 Hamilton Avenue, Palo Alto, California 94301. The business address of Mr. Tinsley is 11600 Sunrise Valley Drive, Reston, Virginia 20191. The business address of Mr. Wong is 24 Raffles Place, 29-04 Clifford Center, Singapore 048621. Messrs. Esser, Kern and Wendelstadt are citizens of Germany; Mr. Engstrom is a citizen of Sweden; and Mr. Wong is a citizen of Singapore. Each of the GAP Managing Members, other than Messrs. Engstrom, Esser, Kern, Wendelstadt and Wong, is a citizen of the United States. The present principal occupation or employment of each of the GAP Managing Members is as a managing member of GAP.

None of the Reporting Persons and none of the above individuals has, during the last five years, been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or subject to any judgment, decree or final

744290305

Page 10 of 22

order finding any violation of federal or state securities laws or enjoining future violations of, or prohibiting or mandating activities subject to, such laws.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

ITEM 3 IS HEREBY AMENDED AND RESTATED IN ITS ENTIRETY AS FOLLOWS:

The Original Schedule 13D was filed as a result of the closing of the transactions, on April 5, 2002, contemplated by the Stock and Warrant Purchase Agreement, dated March 26, 2002, by and among the Company, GAP 74, GAPCO II, GapStar and KG (the "Original Stock Purchase Agreement"), pursuant to which the Company sold to GAP 74, GAPCO II, GapStar and KG an aggregate of 1,569,366 shares of Common Stock at a price per share of \$15.93, resulting in an aggregate purchase price of \$25,000,000 and warrants to purchase 549,279 shares of Common Stock (the "Original Warrants") for an aggregate purchase price of \$25,000. The exercise price for the Original Warrants is \$15.93. The Original Warrants expire on April 5, 2004.

On July 8, 2003, pursuant to the terms of the Original Stock Purchase Agreement, the Company issued and sold to GAP 74, GAPCO II, GapStar and KG warrants to purchase 243,882 shares of Common Stock (the "Additional Warrants") for an aggregate purchase price of \$1,000. The exercise price of the Additional Warrants is \$16.50 per share. The Additional Warrants are exercisable in annual tranches of 81,294 shares based on the periodic achievement of certain revenue thresholds by the Company related to a services agreement the Company entered into on July 3, 2003 with First Data Resources, Inc. The

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

Additional Warrants may not be exercised, if ever, until December 31, 2004, and therefore the Reporting Persons are not currently deemed to "beneficially own" the shares of Common Stock underlying the Additional Warrants (as provided in

744290305

Page 11 of 22

Rule 13d-3(d) of the General Rules and Regulations of the Exchange Act) and they are excluded from the aggregate number of shares listed in this Amendment No. 1.

All of the funds were obtained from contributions from partners of GAP 74, GAPCO II and KG, and advances under an existing credit facility for GapStar.

ITEM 4. PURPOSE OF TRANSACTION.

ITEM 4 IS HEREBY AMENDED AND RESTATED IN ITS ENTIRETY AS FOLLOWS:

The Reporting Persons acquired (or will be acquiring) beneficial ownership of the shares of Common Stock described in this Amendment No. 1 for investment purposes. From time to time the Reporting Persons may acquire additional shares of Common Stock and dispose of some or all of the shares of Common Stock owned by them. Additionally, on the date that is sixty days prior to the first date that the Additional Warrants may be exercised, and on each of the two succeeding anniversaries of such date, the Reporting Persons may acquire beneficial ownership of up to an additional 81,294 shares of Common Stock underlying the Additional Warrants.

Under the terms of the Original Stock Purchase Agreement, Braden R. Kelly was appointed to the Board of Directors of the Company (the "Board of Directors") effective as of April 5, 2002, and the Company is obligated to create an additional vacancy on the Board of Directors and to cause such vacancy to be filled by a nominee of GAP 74.

This Amendment No. 1 is being filed as a result of GAP 74, GAPCO II, GapStar and KG (the "GA Signatories") entering into a Voting Agreement, dated as of December 5, 2003 (the "Voting Agreement"), with Planvista Corporation, a Delaware corporation ("Planvista"), and the Company, pursuant to which the GA Signatories agreed, among other things, to vote (and grant a proxy to Planvista and certain of its

744290305

Page 12 of 22

executive officers to vote) all of the shares of Common Stock held by the GA Signatories (i) in favor of the adoption of the Merger Agreement (as defined in Item 6 below) and the approval of other actions contemplated by the Merger Agreement and any actions required in furtherance thereof, (ii) in favor of the approval of the issuance of shares of Common Stock in connection with the Merger (as defined in Item 6 below) pursuant to the terms of the Merger Agreement and pursuant to the Second Stock Purchase Agreement (as defined below), (iii) in favor of the amendment to the Company's Articles of Incorporation to increase the authorized number of shares of Common Stock to 30 million, (iv) against any action or agreement that would result in a breach in any respect of any covenant, representation or warranty or any other obligation or agreement of the

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

Company or its wholly owned subsidiary, Planet Acquisition Corp., a Delaware corporation ("Merger Sub") under the Merger Agreement or the Voting Agreement, and (v) against any action or agreement that would reasonably be expected to impede, interfere with, delay or attempt to discourage the Merger.

Simultaneously with the execution of the Voting Agreement, the Company entered into a Stock Purchase Agreement, dated as of December 5, 2003 (the "Second Stock Purchase Agreement"), with General Atlantic Partners 77, L.P., a Delaware limited partnership ("GAP 77"), GAPCO II, GapStar, KG and certain other parties named therein pursuant to which the Company agreed to issue and sell to GAP 77, GAPCO II, GapStar and KG and such persons agreed, subject to the satisfaction of certain conditions, to purchase an aggregate of 1,263,157 shares of Common Stock (the "Second Purchased Shares") at a price per share of \$14.25, resulting in an aggregate purchase price of \$17,999,987.25. Upon consummation of the transactions contemplated by the Second Stock Purchase Agreement, the Reporting Persons will each beneficially own all of the

744290305

Page 13 of 22

Second Purchased Shares and GAP 77 will beneficially own all of the shares of Common Stock described in this Amendment No. 1 and all of the Second Purchased Shares. The consummation of the transactions contemplated by the Second Stock Purchase Agreement may not close within the next 60 days, and therefore the Reporting Persons are not currently deemed to "beneficially own" the Second Purchased Shares (as provided in Rule 13d-3(d) of the General Rules and Regulations of the Exchange Act) and they are excluded from the aggregate number of shares listed in this Amendment No. 1.

The Voting Agreement, Merger Agreement and Second Stock Purchase Agreement are described in greater detail in Item 6 below.

None of the Reporting Persons has any other plans which relate to or would result in any of the items listed in paragraphs (a) through (j) of Item 4.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

ITEM 5 IS HEREBY AMENDED AND RESTATED IN ITS ENTIRETY AS FOLLOWS:

(a) As of the date hereof, GAP, GAP 74, GAPCO II, GapStar, KG and GmbH Management each own of record or have the right to exercise Original Warrants for, no shares of Common Stock, 1,741,258 shares of Common Stock, 236,441 shares of Common Stock, 137,457 shares of Common Stock, 3,471 shares of Common Stock and no shares of Common Stock, respectively, representing 0.0%, 23.7%, 3.2%, 1.9%, 0.05% and 0.0% of the Company's issued and outstanding shares of Common Stock, assuming the exercise of all of the Original Warrants.

By virtue of the fact that (i) the GAP Managing Members (other than Mr. Esser) are also the general partners authorized and empowered to vote and dispose of the securities held by GAPCO II, (ii) GAP is the general partner of GAP 74 and the managing member of GapStar and (iii) the GAP Managing Members are authorized and

744290305

Page 14 of 22

empowered to vote and dispose of the securities held by KG, the Reporting Persons may be deemed to share voting power and the power to direct the disposition of the shares of Common Stock, which each owns of record. As of the date hereof, each of the Reporting Persons may be deemed to own beneficially an aggregate of 2,118,645 shares of Common Stock, or 28.9% of the Common Stock assuming exercise of all of the Original Warrants.

(b) Each of the Reporting Persons has the shared power to direct the vote and the shared power to direct the disposition of the 2,118,645 shares of Common Stock that may be deemed to be owned beneficially by each of them.

(c) Except as set forth herein, to the knowledge of the Reporting Persons with respect to the persons named in response to paragraph (a), none of the persons named in response to paragraph (a) has effected any transactions in shares of Common Stock during the past 60 days.

(d) No person other than the persons listed is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities owned by any member of the group.

(e) Not Applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIP WITH RESPECT TO THE ISSUER.

ITEM 6 IS HEREBY AMENDED AND RESTATED IN ITS ENTIRETY AS FOLLOWS:

As noted above, the GAP Managing Members (other than Mr. Esser) are authorized and empowered to vote and dispose of the securities held by GAPCO II, and GAP is authorized and empowered to vote and dispose of the securities held by GAP 74 and GapStar. The GAP Managing Members are also authorized and empowered to vote

744290305

Page 15 of 22

and dispose of securities held by KG. Accordingly, GAP and the GAP Managing Members may, from time to time, consult among themselves and coordinate the Common Stock voting and disposition of the shares of the Company's shares of Common Stock, as well as such other action taken on behalf of the Reporting Persons with respect to the Company's shares of Common Stock as they deem to be in the collective interest of the Reporting Persons.

As described in Item 3 above, on March 26, 2002, GAP 74, GAPCO II, GapStar and KG entered into the Original Stock Purchase Agreement pursuant to which GAP 74, GAPCO II, GapStar and KG purchased, on April 5, 2002, an aggregate of 1,569,366 shares of Common Stock for an aggregate purchase price of \$25,000,000 and Original Warrants to purchase 549,279 shares of Common Stock (at an exercise price of \$15.93 per share of Common Stock) for an aggregate purchase price of \$25,000.

Pursuant to the Original Stock Purchase Agreement, the Company appointed Braden R. Kelly to the Board of Directors and agreed to cause another vacancy to be created and appoint a second designee of GAP 74 to fill such

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

vacancy. As long as GAP 74, GAPCO II, GapStar and KG and their affiliates (as defined in Rule 12b-2 of the General Rules and Regulations under the Exchange Act) continue to beneficially own in the aggregate at least the Minimum Ownership Percentage (as defined in the Original Stock Purchase Agreement) at each annual meeting of the stockholders of the Company held for the purpose of electing directors of the Company, GAP 74 shall be entitled to designate two designees to the Board of Directors, which designees shall be reasonably acceptable to the Board of Directors.

Simultaneously with the Original Closing, the Company, GAP 74, GAPCO II, GapStar and KG entered into the Registration Rights Agreement, dated April

744290305

Page 16 of 22

5, 2002 (the "Original Registration Rights Agreement"). Pursuant to the Original Registration Rights Agreement, GAP 74, GAPCO II, GapStar and KG, as a group, have one demand registration right for an underwritten offering and customary "piggy-back" registration rights pursuant to which they will have a right to participate in registrations initiated by the Company or other stockholders of the Company. Additionally, GAP 74, GAPCO II, GapStar and KG have the right to request that the Company file a "shelf" registration statement on Form S-3 under the Securities Act, allowing for public sales of some or all of the shares of Common Stock held by such parties on a continuous basis.

The Company and Merger Sub entered into an Agreement and Plan of Merger, dated as of December 5, 2003 (the "Merger Agreement"), with Planvista, pursuant to which Merger Sub will be, subject to the closing conditions set forth in the Merger Agreement, merged with and into Planvista (the "Merger"), with all of the outstanding capital stock of Planvista being converted into the right to receive shares of Common Stock, as set forth in the Merger Agreement.

To induce Planvista to enter into the Merger Agreement, the GA Signatories have entered into the Voting Agreement described in Item 4 above, pursuant to which they have agreed, among other things, to vote (and grant a proxy to Planvista and certain of its executive officers to vote) all of the shares of Common Stock held by the GA Signatories (i) in favor of the adoption of the Merger Agreement and the approval of other actions contemplated by the Merger Agreement and any actions required in furtherance thereof, (ii) in favor of the approval of the issuance of shares of Common Stock in connection with the Merger pursuant to the terms of the Merger Agreement and pursuant to the Second Stock Purchase Agreement, (iii) in favor of the amendment to the Company's Articles of Incorporation to increase the authorized number of shares of

744290305

Page 17 of 22

Common Stock to 30 million, (iv) against any action or agreement that would result in a breach in any respect of any covenant, representation or warranty or any other obligation or agreement of the Company or Merger Sub under the Merger Agreement or the Voting Agreement, and (v) against any action or agreement that would reasonably be expected to impede, interfere with, delay or attempt to discourage the Merger. However, the GA Signatories are not obligated to vote in favor of the foregoing actions if the Board of Directors withholds, withdraws,

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

amends or modifies its recommendation in favor of the Merger as permitted pursuant to the Merger Agreement. In addition, through and until the consummation of the Merger or the termination of the Merger Agreement in accordance with its terms, the GA Signatories have agreed not to transfer their shares of Common Stock.

Simultaneously with the signing of the Merger Agreement, the Company, GAP 77, GAPCO II, GapStar, KG and certain other parties named therein entered into the Second Stock Purchase Agreement pursuant to which, as described in Item 4 above, the Company agreed to issue and sell to GAP 77, GAPCO II, GapStar and KG, and such persons agreed, subject to the satisfaction of certain conditions, to purchase an aggregate of 1,263,157 shares of Common Stock at a price per share of \$14.25, resulting in an aggregate purchase price of \$17,999,987.25.

Pursuant to the terms of the Second Stock Purchase Agreement, GAP 77, GAP 74, GAPCO II, GapStar and KG have agreed to a one year "lock-up" provision with respect to all but 434,568 shares of Common Stock beneficially owned by each of GAP 77, GAP 74, GAPCO II, GapStar and KG on the date hereof or purchased pursuant to the Second Stock Purchase Agreement (the "Restricted Shares"). Accordingly, GAP 77, GAP 74, GAPCO II, GapStar and KG may not transfer any Restricted Shares prior to the

744290305

Page 18 of 22

first anniversary of the closing date of the purchase of shares pursuant to the Second Stock Purchase Agreement (which is expected to be simultaneously with the consummation of the Merger), except (i) GAP 77, GAP 74, GAP Coinvestment, GapStar and KG may transfer, in the aggregate, so many Restricted Shares in any three month period as would be permitted pursuant to Rule 144(e)(1)(i) promulgated by the Securities and Exchange Commission under the Securities Act of 1933 (as in effect on December 5, 2003) whether or not Rule 144(e)(1)(i) is applicable and whether or not the other conditions set forth in Rule 144 are satisfied, (ii) to affiliates of GAP 77, GAP 74, GAP Coinvestment, GapStar or KG, (iii) in connection with a sale of the Company and (iv) in any other transfer which has been approved in advance by the Board of Directors.

As a condition to closing the transactions contemplated by the Second Stock Purchase Agreement, the Company, GAP 77, GAP 74, GAPCO II, GapStar, KG and certain other parties named therein are expected to enter into an Amended and Restated Registration Rights Agreement (the "Amended and Restated Registration Rights Agreement") pursuant to which GAP 77, GAP 74, GAPCO II, GapStar and KG will have the same registration rights described above in the Original Registration Rights Agreement. The primary purpose for entering into the Amended and Restated Registration Rights Agreement is to add GAP 77 and certain other unrelated persons as a party thereto.

The foregoing summaries of the Original Stock Purchase Agreement, the Original Warrants, the Original Registration Rights Agreement, the Merger Agreement, the Second Stock Purchase Agreement, the Voting Agreement and the Amended and Restated Registration Rights Agreement are qualified in their entirety by reference to Exhibits 4, 5, 6, 7, 8, 9 and 10 which are incorporated by reference herein.

744290305

Page 19 of 22

ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.

- Exhibit 1: Agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
- Exhibit 2: Power of Attorney dated December 20, 2002 appointing Thomas J. Murphy Attorney-in-Fact for GAP.
- Exhibit 3: Power of Attorney dated December 20, 2002 appointing Thomas J. Murphy Attorney-in-Fact for GAPCO II.
- Exhibit 4: Stock and Warrant Purchase Agreement, dated March 26, 2002, by and among ProxyMed, Inc., General Atlantic Partners 74, L.P., GAP Coinvestment Partners II, L.P., GapStar, LLC and GAPCO GmbH & Co. KG (incorporated by reference to Exhibit 10.1 of the Company's Form 8-K as filed with the Securities and Exchange Commission on March 29, 2002).
- Exhibit 5: Form of Common Stock Purchase Warrants (incorporated by reference to Exhibit 5 of the Original Schedule 13D as filed with the Securities and Exchange Commission on April 8, 2002).
- Exhibit 6: Form of Registration Rights Agreement by and among ProxyMed, Inc., General Atlantic Partners 74, L.P., GAP Coinvestment Partners II, L.P., GapStar, LLC and GAPCO GmbH & Co. KG (incorporated by reference to Exhibit 10.3 of the Company's Form 8-K as filed with the Securities and Exchange Commission on March 29, 2002).
- Exhibit 7: Agreement and Plan of Merger, dated as of December 5, 2003, by and among the Company, Merger Sub and Planvista (incorporated by reference to Exhibit 2.1 of Form S-4 as filed by the Company with the Securities and Exchange Commission on December 9, 2003).

744290305

Page 20 of 22

- Exhibit 8: Stock Purchase Agreement, dated as of December 5, 2003, by and among the Company, GAP 77, GAPCO II, GapStar, KG and certain other parties named therein (incorporated by reference to Exhibit 2.2 of Form S-4 as filed by the Company with the Securities and Exchange Commission on December 9, 2003).

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

Exhibit 9: Voting Agreement, dated as of December 5, 2003, by and among Planvista, the Company, GAP 74, GAPCO II, GapStar, and KG (incorporated by reference to Exhibit 10.2 of Form S-4 filed by the Company with the Securities and Exchange Commission on December 9, 2003).

Exhibit 10: Form of Amended and Restated Registration Rights Agreement, by and among the Company, GAP 74, GAP 77, GAPCO II, GapStar, KG and certain other parties named therein.

744290305

Page 21 of 22

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated December 10, 2003.

GENERAL ATLANTIC PARTNERS, LLC

By: /s/ Thomas J. Murphy

Name: Thomas J. Murphy
Title: Attorney-in-Fact

GENERAL ATLANTIC PARTNERS 74, L.P.

By: General Atlantic Partners, LLC,
Its general partner

By: /s/ Thomas J. Murphy

Name: Thomas J. Murphy
Title: Attorney-in-Fact

GAP COINVESTMENT PARTNERS II, L.P.

By: /s/ Thomas J. Murphy

Name: Thomas J. Murphy
Title: Attorney-in-Fact

GAPSTAR, LLC

By: General Atlantic Partners, LLC,
Its managing member

By: /s/ Thomas J. Murphy

Edgar Filing: PROXYMED INC /FT LAUDERDALE/ - Form SC 13D/A

Name: Thomas J. Murphy
Title: Attorney-in-Fact

GAPCO GMBH & CO. KG

By: GAPCO Management GmbH,
Its general partner

By: /s/ Thomas J. Murphy

Name: Thomas J. Murphy
Title: Procuration Officer

744290305

Page 22 of 22

GAPCO MANAGEMENT GMBH

By: /s/ Thomas J. Murphy

Name: Thomas J. Murphy
Title: Procuration Officer